- Home
- AYTU vs DYAI Comparison
AYTU vs DYAI Comparison
Compare AYTU & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AYTU | DYAI |
|---|---|---|
| Founded | N/A | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 32.5M |
| IPO Year | 2015 | 2003 |
Fundamental Metrics
Financial Performance| Metric | AYTU | DYAI |
|---|---|---|
| Price | $2.45 | $0.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $9.33 | $3.00 |
| AVG Volume (30 Days) | 29.6K | ★ 64.7K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,632,080.00 | $3,090,345.00 |
| Revenue This Year | N/A | $122.79 |
| Revenue Next Year | $43.75 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 277.47 | N/A |
| 52 Week Low | $1.26 | $0.65 |
| 52 Week High | $3.07 | $1.35 |
Technical Indicators
Market Signals| Indicator | AYTU | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 39.46 | 37.93 |
| Support Level | $2.15 | $0.71 |
| Resistance Level | $2.64 | $0.99 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 1.96 | 6.84 |
Price Performance
Historical ComparisonAbout AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
About DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.